06. 09. 2021

Phesi data show clinical trial suspensions continue to rise as covid-19 impact on development persists

Connecticut, USA – Phesi Inc., a data-driven provider of AI-powered clinical development analytics products and solutions, today announced it has entered into an exclusive strategic collaboration with clinical AI technology
company, Sensyne Health…

Read more
06. 09. 2021

Phesi and Sensyne Health agree collaboration to advance development of synthetic arms in clinical trials

January 5th, 2021 – Connecticut, USA – Phesi Inc., a data-driven provider of AI-powered clinical development analytics products and solutions, today announced it has entered into an exclusive strategic collaboration with clinical AI technology company, Sensyne Health (LSE: SENS), which is making an equity investment of $10 million in Phesi…

Read more
01. 22. 2019

Phesi at the 8th crown congress

Connecticut, USA – Phesi Inc., a data-driven provider of AI-powered clinical development analytics products and solutions, today announced it has entered into an exclusive strategic collaboration with clinical AI technology
company, Sensyne Health…

Read more
10. 10. 2018

Phesi selected as finalist for 2018 scrip award

Connecticut, USA – Phesi Inc., a data-driven provider of AI-powered clinical development analytics products and solutions, today announced it has entered into an exclusive strategic collaboration with clinical AI technology
company, Sensyne Health…

Read more